RISA Labs Raises $11 Mn From Cencora Ventures, Optum Ventures

SUMMARY

The funding round saw participation from Oncology Ventures, z21 Ventures, and General Catalyst cofounder John Simon via VentureForGood

The fresh capital will boost the distribution of RISA’s system to cancer clinics, health systems, specialty pharmacies and infusion networks across the US

RISA Labs previously raised $3.5 Mn from investors such as Odd Bird VC, Helion Ventures cofounder Ashish Gupta, among others

Healthcare AI startup RISA Labs has raised $11.1 Mn (over INR 100 Cr) in a Series A funding round co-led by US-based VC firms Cencora Ventures and Optum Ventures. Besides, investors like Oncology Ventures, z21 Ventures, and General Catalyst cofounder John Simon via VentureForGood also participated in the round.

The fresh capital will boost the distribution of RISA’s system to cancer clinics, health systems, specialty pharmacies and infusion networks across the US, the Palo Alto-based startup said in a statement.

Founded in June 2024 by Kshitij Jaggi and Kumar Shivang, RISA’s AI-powered console, BOSS, that simplifies complex oncology workflows by breaking them into smaller tasks handled by AI agents. The AI OS is purpose-built for the realities of cancer care, handling complex payer rules, multi-drug regimens, and disease-specific requirements.

The AI integrated in its offering aims to address the core mathematical problem in modern cancer care.

Featured in Inc42’s 30 Startups To Watch in April 2025, the startup previously raised $3.5 Mn from investors such as Odd Bird VC, Helion Ventures cofounder Ashish Gupta and Flipkart cofounder Binny Bansal, among others.

The startup claimed that RISA is live at some of the largest oncology practices in the US, where in a particular unit, about 80% of administrative staff time has been freed up, denials have been reduced by up to 40%, and first-pass approval rates have reached 97.8%.

In 2026, RISA will go deeper in oncology, partnering with ecosystem leaders to expand AI-driven workflows across the full continuum of cancer care, the San Francisco-based startup said.

The development comes at a time when the healthcare sector has been seeing an uptick in investors’ interest on the back of increased AI integration that assures higher accuracy in medical test results and shrinks the treatment or diagnosis timeline than manual intervention.

Healthtech space emerged as one of the top 10 funded business sectors in the Indian startup ecosystem in 2025, where more than $700 Mn were infused in this space across 54 deals in the past year, based on the Inc42 Startup Trends report.

About two months ago, Bengaluru-based biotech startup CrisprBits secured $3 Mn (INR 26.8 Cr) to commercialise its PathCrisp molecular diagnostics platform and augment the production capacity for high-impact tests.